StackItSmart

Compound reference

Epithalon

Epitalon

Peptides4 cited findingsClinical review: not reviewed

Identity & applicability

Regulatory recordSupporting passage inspected

Epitalon (also spelled epithalon) is a tetrapeptide. FDA explicitly distinguishes it from epithalamin, a pineal-gland polypeptide extract; findings for the extract should not be attributed to the tetrapeptide.[1]

  • Similar names do not establish identical composition or clinical effects.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

· Fresh scoped source inspection; locator/date corrections and original full-text evidence recorded. Independent editorial review pending; no qualified clinical review.

· Independent editorial worker reopened the cited support; coordinator resolved the requested bibliography corrections and integrated the bounded claim. Original and corrected cell figures remain scientifically inconsistent as stated. No qualified clinical review.

Clinical & experimental findings

Regulatory recordSupporting passage inspected

FDA’s 2026 review identified human biomarker research but no clinical insomnia outcome evidence sufficient to establish epitalon effectiveness. A change in melatonin or a laboratory aging marker is not evidence of longer human life.[1]

  • The review does not establish a quantified benefit or harm for longevity uses.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.

· Fresh scoped source inspection; locator/date corrections and original full-text evidence recorded. Independent editorial review pending; no qualified clinical review.

· Independent editorial worker reopened the cited support; coordinator resolved the requested bibliography corrections and integrated the bounded claim. Original and corrected cell figures remain scientifically inconsistent as stated. No qualified clinical review.

Human observational studySupporting passage inspected

A historical Epitalon report in retinitis pigmentosa included a conventional-treatment comparison group. It reported retinal functional changes, but allocation, masking and analysis were insufficiently described to establish treatment effectiveness.[2]

  • Parabulbar administration and a historical eye-disease population do not establish systemic anti-aging effects.
  • Eye-level outcomes are clustered within patients; the report does not establish a rigorous randomized trial.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Fresh source inspection of specified original sections; proposed addition awaits independent editorial review.

· Independent editorial worker reopened the cited support; coordinator resolved the requested bibliography corrections and integrated the bounded claim. Original and corrected cell figures remain scientifically inconsistent as stated. No qualified clinical review.

Animal / laboratorySupporting passage inspected

A 2025 cell-culture paper reported telomere-related changes, but a subsequent correction replaced its figures. Some corrected normal-cell panels do not agree with the article's claims of statistical significance. These unresolved laboratory findings do not establish human longevity or safety.[3][4]

  • Corrected Figure 1C and Figure 2G are marked ns; Figure 1D image label and caption disagree.
  • Treatment-unit and figure-panel inconsistencies remain unresolved; no clinical cancer-risk estimate follows from these experiments.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Fresh source inspection of specified original sections; proposed addition awaits independent editorial review.

· Independent editorial worker reopened the cited support; coordinator resolved the requested bibliography corrections and integrated the bounded claim. Original and corrected cell figures remain scientifically inconsistent as stated. No qualified clinical review.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Corrected the molecular identity distinction using FDA’s explicit footnote and separated biomarkers from clinical outcomes.

  • Human lifespan benefit, clinical insomnia efficacy and formulation-specific kinetics remain unverified.
  • Other inherited assertions not supported by the published claim set remain unverified; no qualified clinician review has occurred.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

  1. FDA July 2026 Pharmacy Compounding Advisory Committee briefing: Epitalon

    US Food and Drug Administration. 2026-07. Regulatory document.

    Inspected location: PDF p. 8, footnote 6; PDF p. 10, identity table; PDF pp. 25–28, human effectiveness/insomnia; PDF pp. 34–35, tumor-study limitations

    Study context and inspection record
  2. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa.

    Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Neuro Endocrinol Lett. 2002 Aug;23(4):365–368. PMID:12195242. 2002-08. PMID:12195242 Full text inspected.

    Inspected location: Scanned original p. 366, Methods, and p. 367, Table II / Results visually inspected

    Study context and inspection record
  3. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.

    Al-Dulaimi S, Thomas R, Matta S, Roberts T. Biogerontology. 2025;26(5):178. Published online 2025-09-04. DOI:10.1007/s10522-025-10315-x. 2025-09-04. PMID:40908429 · DOI:10.1007/s10522-025-10315-x Full text inspected.

    Inspected location: Full HTML treatment/qPCR/TRAP/C-circle/PML/statistics; Results/Discussion/change history/corrected captions; PMC updated Results and corrected Figure 1-3 crosschecked with correction

    Study context and inspection record
  4. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.

    Al-Dulaimi S, Thomas R, Matta S, Roberts T. Biogerontology. 2026;27(1):1. Published online 2025-11-15. DOI:10.1007/s10522-025-10326-8. 2025-11-15. PMID:41240216 · DOI:10.1007/s10522-025-10326-8 Full text inspected.

    Inspected location: Entire correction HTML text and original/corrected captions; Corrected Figure 1, Figure 2 and Figure 3 PMC CDN images visually inspected

    Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts
  • peptide-fda-epithalon-2026: Identity p. 8, footnote 6; clinical effectiveness pp. 25–28
  • July 23–24, 2026 FDA compounding advisory meeting page checked; committee review distinguished from approval.

View this compound in the research library →

Related records in this class

Grouped under Peptides for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.

StackItSmart

Age confirmation

This reference discusses steroids, SARMs and other compounds. It is educational, not medical advice, and does not recommend using or combining them.

Your confirmation is saved in this browser when storage is available.